WHAT IT IS
PEA is a fatty acid amide your body produces itself. It's a cousin of anandamide, the "bliss molecule" in the endocannabinoid system. It was first isolated and described in 1957, and it has been studied for neuropathic and chronic pain since 1975. Small amounts are also found in foods like egg yolk, soybeans and peanuts.
PEA is extremely fat-soluble and barely dissolves in water. That matters for supplements: your gut absorbs it far better when there's fat taken with it, because dietary fat triggers bile, which helps dissolve fat-soluble compounds so they can be absorbed. Taken on an empty stomach, much of it passes straight through.
HOW AND WHY YOUR BODY MAKES IT
PEA is made "on demand" from the fats in your cell membranes. It starts out as NAPE (N-acyl-phosphatidylethanolamine), a fat molecule built into the cell membrane that acts as PEA's stored precursor. When a cell is injured or inflamed, an enzyme called NAPE-PLD (NAPE-specific phospholipase D) cuts NAPE apart, releasing free PEA.
Once PEA has done its job, two enzymes break it down. FAAH (fatty acid amide hydrolase) works throughout the body and also breaks down anandamide, the "bliss molecule". NAAA (N-acylethanolamine acid amidase) works mainly inside immune cells and prefers PEA specifically. Because these two enzymes control how long PEA lasts, researchers are studying drugs that block them to raise the body's own PEA levels.
Your cells ramp up production in response to injury, stress and inflammation. It's a built-in brake that tells the immune system to calm down once the job is done. Nobel laureate Rita Levi-Montalcini's group called this "ALIA" (Autacoid Local Injury Antagonism): a local signal made at the site of damage to stop inflammation spiralling out of control.
HOW IT WORKS
PEA is one of the body's own activators of PPAR-alpha, a nuclear receptor that acts as a lipid messenger regulating inflammation and chronic pain. Activating it switches off pro-inflammatory genes.
It also calms mast cells, the allergy and inflammation cells that release histamine when they "degranulate", and glial cells (microglia and astrocytes), which drive the "central sensitisation" that keeps chronic pain going.
On top of that, it produces an "entourage effect". It doesn't bind strongly to the CB1 or CB2 cannabinoid receptors itself, but it boosts your own endocannabinoids and acts on TRPV1 and GPR55. That gives a cannabinoid-like effect without any high.
THE EVIDENCE FOR CHRONIC PAIN
A 2023 meta-analysis by Lang-Illievich and colleagues, published in Nutrients, pooled 11 double-blind trials with a combined sample size of 774 patients. The authors concluded that PEA is an effective and well-tolerated treatment for chronic pain.
A larger 2025 meta-analysis by Del Giorno and colleagues, covering 18 studies and 1196 patients, found it effective for nociceptive, nociplastic and neuropathic pain, with benefits measured for up to about six months.
THE NNT, AND WHAT IT ACTUALLY MEANS
NNT (number needed to treat) is how many people need to take a treatment for one extra person to get at least 50% pain relief compared with placebo. Lower is better: 1 would mean everyone responds, while 10 means only 1 in 10 benefits beyond placebo.
In the largest PEA trial, a double-blind study of 636 sciatica patients, the NNT for 50% pain relief was 1.5 after three weeks. An independent reanalysis put it at 1.7 for pain with 600mg a day.
For comparison, a major 2015 Lancet Neurology review of neuropathic pain drugs found NNTs of about 7.7 for pregabalin, 6 to 7 for gabapentin, and 6.4 for SNRIs like duloxetine. So on paper, PEA's NNT of about 1.5 to 1.7 is roughly 4 to 5 times better than first-line drugs like pregabalin (Lyrica) and gabapentin.
There are caveats, so you can judge for yourself. That figure comes mainly from one trial, in sciatica, published in a smaller Spanish journal and later reanalysed, so it isn't a pooled figure across all chronic pain. PEA has not been tested head-to-head against those drugs; the comparison is indirect, across different studies, patients and conditions. Some trials have found little or no effect, and many PEA studies are small or industry-linked. It's promising, cheap and remarkably safe, but bigger independent trials are still needed.
WHERE IT'S FOUND IN THE BODY
Practically everywhere: brain, spinal cord, nerves, skin, gut, immune cells and fat tissue. Because it's a local, on-demand signal, levels rise wherever there's damage or inflammation. That's why it acts on so many different problems.
MY EXPERIENCE: ETD/GLUE EAR AND PEA
For as long as I can remember, my hearing has been muffled, like having cotton wool or water stuck in my ears all the time. It affected everything. I think it's Eustachian tube dysfunction (ETD) or glue ear, and I believe it's driven by allergies, but I've never worked out what I'm actually allergic to.
PEA is the only thing that has ever reliably unmuffled my ears. When I take it, every couple of days with fat, my ears start to fizz, crackle and pop, and then they clear and my hearing opens up again. Nothing else I've tried has done that besides Beconase, which took weeks to work and then my ears would muffle again overnight.
My theory is that it comes down to mast cells. Allergic inflammation is driven by mast cells degranulating, releasing histamine and other chemicals that swell the lining of the nose, sinuses and Eustachian tubes. When the tubes swell shut, the middle ear can't equalise pressure or drain, and hearing goes muffled. PEA calms mast cells and reduces degranulation, so my guess is it shrinks that swelling enough for the tubes to open. That would explain the fizzing and popping as they start working again.
To be clear, there are no clinical trials on PEA for ETD or glue ear that I know of. This is my personal experience and my best guess at the mechanism, not proven science, but I'd love to hear if anyone else with allergic ETD has tried this.
WHAT ELSE IT MAY HELP WITH (RATED BY STRENGTH OF EVIDENCE)
Chronic and nerve pain, about 80%. This is the best-studied use, with multiple meta-analyses of double-blind trials (see the evidence section above). Sciatica and carpal tunnel have the strongest individual trial results.
Colds and flu, about 55%. Before PEA was ever used for pain, it was sold as a medicine in Czechoslovakia from the 1970s under the brand name Impulsin, for preventing and treating flu and respiratory infections. A 2013 review notes that 6 clinical trials in a total of nearly 4000 people were performed and published last century, specifically studying PEA as a therapy for influenza and the common cold, with positive results. These trials are old and wouldn't meet modern standards, but it's a large and interesting body of work.
Skin inflammation and eczema, about 45%. PEA creams have been studied for atopic eczema and itch, likely through calming mast cells and inflammation in the skin.
Eye pressure in glaucoma, about 35%. A few small Italian studies found it lowered raised eye pressure.
Allergies and asthma, about 25% (promising, but animal studies only). Mast cells are central to allergic asthma: they release histamine and leukotrienes, chemicals that tighten and inflame the airways. In a 2017 mouse study, PEA given during allergen exposure prevented OVA-induced bronchial hyperreactivity, meaning the airways didn't become twitchy and over-reactive to the allergen (OVA, or ovalbumin, is an egg protein used to make mice allergic). The researchers also found a significant inhibitory action of PEA on pulmonary mast cell recruitment and degranulation, an effect coupled to a reduction of leukotriene C4 production. Strikingly, allergen exposure lowered the mice's own PEA levels in their airways. That suggests taking it daily could, in theory, help prevent asthma flare-ups by keeping mast cells calmer before an attack starts.
That's my reading, though: the authors only concluded that supplementation has the potential to prevent the development of asthma-like features, and no human asthma trials exist yet that I know of. If you have asthma, never swap your inhalers for PEA. At most, it's something to add on.
SAFETY AND ALLERGY
Because your body makes it constantly, a true allergy to PEA itself is extremely unlikely. Any reaction is more likely to come from the other ingredients in a supplement, such as fillers, capsule material or dispersing agents, so check labels if you're sensitive.
A 2016 pharmacology review found that for treatment up to 49 days, the current clinical data argue against serious adverse drug reactions at a rate of 1 in 200 or more, though data beyond about two months are thinner. There are no known dangerous drug interactions, and no dependence, tolerance or high. Reported side effects are rare and mild, such as stomach upset or tiredness. (nih)
PRACTICAL INFO PEOPLE ASK ABOUT
Take it with some fat, I personally use coconut oil, but you can use eggs, oily fish, olive oil, nuts, full-fat dairy, because it absorbs much better that way. Micronised or ultramicronised forms have far smaller particles, so more surface area dissolves and gets absorbed. "Dispersible" versions add carriers that do a similar job, and these are the forms most trials used.
Most trials used 600 to 1200mg a day, often split into two or three doses, each with food. For pain, effects usually build over two to four weeks, so it isn't an instant painkiller like ibuprofen, but can be taken alongside any known pain medication.
SOURCES
Lang-Illievich et al. 2023: https://pmc.ncbi.nlm.nih.gov/articles/PMC10053226/
Keppel Hesselink and Kopsky 2015: https://pmc.ncbi.nlm.nih.gov/articles/PMC4631430
Cruccu et al. 2019 NNT reanalysis: https://www.eurekaselect.com/article/99363
Finnerup et al. 2015, Lancet Neurology: https://pubmed.ncbi.nlm.nih.gov/25575710/
Gabrielsson et al. 2016 safety review: https://pubmed.ncbi.nlm.nih.gov/27220803/
Del Giorno 2025 summary: https://wikimsk.org/wiki/Palmitoylethanolamide